Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group.

Antineoplastic Combined Chemotherapy Protocols / therapeutic use Capecitabine Humans Receptor, ErbB-2 Retrospective Studies Stomach Neoplasms / pathology Trastuzumab / therapeutic use

Chemotherapy Gastric cancer HER2 Maintenance Trastuzumab

Journal

Journal of gastrointestinal cancer

ISSN: 1941-6636

Titre abrégé: J Gastrointest Cancer

Pays: United States

ID NLM: 101479627

Informations de publication

Date de publication:
Jun 2022

Historique:

accepted: 24 01 2021

pubmed: 5 2 2021

medline: 10 6 2022

entrez: 4 2 2021

Statut: ppublish

Résumé

In the ToGA trial for HER2-positive advanced gastric cancer, cisplatin plus fluoropyrimidine was given for 6 cycles; trastuzumab was given until disease progression. However, there is a lack of real-life data about trastuzumab maintenance after 6 cycle chemotherapy. This study aims to present real-life data of trastuzumab ± capecitabine maintenance after 6 cycles of platinum, fluoropyrimidine, and trastuzumab in non-progressive patients. This is a retrospective multicenter study of the Turkish Oncology Group. A total of 35 HER2-positive, inoperable locally advanced, recurrent, or metastatic gastric adenocarcinoma patients being non-progressive at the end of 6 cycle chemotherapy and being given trastuzumab ± capecitabine as maintenance treatment were included from sixteen oncology centers. Baseline characteristics, objective tumor responses, progression free and overall survival data, and toxicities were determined. About 68% of the patients were given CF, and 32% were given FOLFOX with trastuzumab as the first-line treatment. The best response in 6 cycle chemotherapy was complete 8 (22%), partial 24 (68%), and stable disease 3 (8%). All patients had trastuzumab maintenance (median cycle 13; range 7-51), and 49% of the patients had capecitabine with trastuzumab (median capecitabine cycle 6; range 2-30). The median PFS of the patients was 12.0 months (95% CI 10.3-13.7), and median OS was 17.4 months (95% CI 15.2-19.5). There were 2 patients with grade 1 cardiotoxicity. Trastuzumab maintenance ± capecitabine after 6 cycles of trastuzumab plus combined chemotherapy treatment revealed efficacy and safety in non-progressive HER2-positive advanced gastric cancer.

Identifiants

DOI: 10.1007/s12029-021-00594-1 PMID: 33538958

pubmed: 33538958

doi: 10.1007/s12029-021-00594-1

pii: 10.1007/s12029-021-00594-1

doi:

Substances chimiques

Capecitabine 6804DJ8Z9U

Receptor, ErbB-2 EC 2.7.10.1

Trastuzumab P188ANX8CK

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

Pagination

282-288

Informations de copyright

Références

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492 .

doi: 10.3322/caac.21492 pubmed: 30207593

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. https://doi.org/10.1016/s0140-6736(10)61121-x .

doi: 10.1016/s0140-6736(10)61121-x pubmed: 20728210

Koopman T, Smits MM, Louwen M, Hage M, Boot H, Imholz AL. HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison. J Cancer Res Clin Oncol. 2015;141(8):1343–51. https://doi.org/10.1007/s00432-014-1900-3 .

doi: 10.1007/s00432-014-1900-3 pubmed: 25544671

Fornaro L, Vivaldi C, Parnofiello A, Ugolini C, Aprile G, De Maglio G, et al. Validated clinico-pathologic nomogram in the prediction of HER2 status in gastro-oesophageal cancer. Br J Cancer. 2019;120(5):522–6. https://doi.org/10.1038/s41416-019-0399-4 .

doi: 10.1038/s41416-019-0399-4 pubmed: 30745584 pmcid: 6461920

Liang Z, Zeng X, Gao J, Wu S, Wang P, Shi X, et al. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer. 2008;8:363. https://doi.org/10.1186/1471-2407-8-363 .

doi: 10.1186/1471-2407-8-363 pubmed: 19061514 pmcid: 2613415

Ter Veer E, Creemers A, de Waal L, van Oijen MGH, van Laarhoven HWM. Comparing cytotoxic backbones for first-line trastuzumab-containing regimens in human epidermal growth factor receptor 2-positive advanced oesophagogastric cancer: a meta-analysis. Int J Cancer. 2018;143(2):438–48. https://doi.org/10.1002/ijc.31325 .

doi: 10.1002/ijc.31325 pubmed: 29451302

Gong J, Liu T, Fan Q, Bai L, Bi F, Qin S, et al. Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial. BMC Cancer. 2016;16:68. https://doi.org/10.1186/s12885-016-2092-9 .

doi: 10.1186/s12885-016-2092-9 pubmed: 26857702 pmcid: 4746787

Soularue E, Cohen R, Tournigand C, Zaanan A, Louvet C, Bachet JB, et al. Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. Bull Cancer. 2015;102(4):324–31. https://doi.org/10.1016/j.bulcan.2014.08.001 .

doi: 10.1016/j.bulcan.2014.08.001 pubmed: 25744576

Li Q, Lv M, Jiang H, Wang Y, Yu S, Li W, et al. A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy. J Cancer Res Clin Oncol. 2020;146(1):287–95. https://doi.org/10.1007/s00432-019-03060-5 .

doi: 10.1007/s00432-019-03060-5 pubmed: 31667572

Ilhan-Mutlu A, Taghizadeh H, Beer A, Dolak W, Ba-Ssalamah A, Schoppmann SF, et al. Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: a retrospective single center analysis. Cancer Biol Ther. 2018;19(3):169–74. https://doi.org/10.1080/15384047.2017.1414759 .

doi: 10.1080/15384047.2017.1414759 pubmed: 29252101 pmcid: 5790357

Lopez A, Chen H-C, Harada K, Murphy MAB, Rogers JE, Thomas I et al. Maintenance therapy with trastuzumab +/- fluoropyrimidine in non-progressive HER-2 positive advanced gastroesophageal cancer patients after first-line chemotherapy. J Clin Oncol. 2018;36(15_suppl):e16071-e. https://doi.org/10.1200/JCO.2018.36.15_suppl.e16071 .

Ryu MH, Yoo C, Kim JG, Ryoo BY, Park YS, Park SR, et al. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. Eur J Cancer. 2015;51(4):482–8. https://doi.org/10.1016/j.ejca.2014.12.015 .

doi: 10.1016/j.ejca.2014.12.015 pubmed: 25661103

Kurokawa Y, Sugimoto N, Miwa H, Tsuda M, Nishina S, Okuda H, et al. Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). Br J Cancer. 2014;110(5):1163–8. https://doi.org/10.1038/bjc.2014.18 .

doi: 10.1038/bjc.2014.18 pubmed: 24473399 pmcid: 3950868

Chua C, Tan IB, Yamada Y, Rha SY, Yong WP, Ong WS, et al. Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer. Cancer Chemother Pharmacol. 2015;76(2):397–408. https://doi.org/10.1007/s00280-015-2811-y .

doi: 10.1007/s00280-015-2811-y pubmed: 26099969

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026 .